Unknown

Dataset Information

0

Tumor microenvironment-responsive spherical nucleic acid nanoparticles for enhanced chemo-immunotherapy.


ABSTRACT: Certain chemotherapeutics can induce tumor cells' immunogenic cell death (ICD), release tumor antigens, and thereby trigger personalized antitumor immune responses. Co-delivery of adjuvants using nanocarriers could amplify the ICD-induced tumor-specific immunity achieving a synergistic chemo-immunotherapeutic effect. However, complicated preparation, low drug loading efficiency, and potential carrier-associated toxicity are the major challenges that limited its clinical applications. Herein, a carrier-free core-shell nanoparticle (MPLA-CpG-sMMP9-DOX, MCMD NPs) was constructed by facile self-assembly of spherical nucleic acids (SNA) with two adjuvants of CpG ODN and monophosphoryl lipid A (MPLA) as a core and doxorubicin (DOX) radially around the dual-adjuvants SNA as a shell. The results demonstrated that MCMD NPs could enhance drugs accumulation in tumors, and release DOX upon enzymatic degradation of matrix metalloproteinase-9 (MMP-9) peptide in the tumor microenvironment (TME), which enhanced the direct-killing effect of DOX on tumor cells. The core of MPLA-CpG SNA efficiently boosted the ICD-induced antitumor immune response to further attack tumor cells. Thus, MCMD NPs achieved a synergistic therapeutic effect of chemo-immunotherapy with reduced off-target toxicity. This study provided an efficient strategy for the development of a carrier-free nano-delivery system for enhanced cancer chemo-immunotherapy.

SUBMITTER: Ma B 

PROVIDER: S-EPMC10214549 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Tumor microenvironment-responsive spherical nucleic acid nanoparticles for enhanced chemo-immunotherapy.

Ma Bing B   Ma Yingying Y   Deng Bo B   Xiao Pengjun P   Huang Pengyu P   Wang Dali D   Liu Lanxia L  

Journal of nanobiotechnology 20230526 1


Certain chemotherapeutics can induce tumor cells' immunogenic cell death (ICD), release tumor antigens, and thereby trigger personalized antitumor immune responses. Co-delivery of adjuvants using nanocarriers could amplify the ICD-induced tumor-specific immunity achieving a synergistic chemo-immunotherapeutic effect. However, complicated preparation, low drug loading efficiency, and potential carrier-associated toxicity are the major challenges that limited its clinical applications. Herein, a c  ...[more]

Similar Datasets

| S-EPMC6428072 | biostudies-literature
| S-EPMC10119091 | biostudies-literature
| S-EPMC10603775 | biostudies-literature
| S-EPMC11791960 | biostudies-literature
| S-EPMC10585899 | biostudies-literature
| S-EPMC10742199 | biostudies-literature
| S-EPMC9054608 | biostudies-literature
| S-EPMC9647582 | biostudies-literature
| S-EPMC11843742 | biostudies-literature
| S-EPMC8781438 | biostudies-literature